Clinical and Lab Marker Predicting Early Molecular Response Inpatient of CML Chronic Phase Treated with Imatinib
Choudhary, S.; Singh, J.; Malhotra, H.; Sharma, R.
Journal of the Association of Physicians of India 68(1): 102
2020
ISSN/ISBN: 0004-5772 PMID: 31979945 Document Number: 18073
Imatinib is a tyrosine kinase inhibitor, an initial choice for treating Ph-positive chronic myeloid leukemia in India. Modern oncology is experiencing a paradigm shift toward personalized medicine, which aims to direct medical agents toward the tumor site. It is important to investigate the current development of using molecular information in intelligent models for personalized medicine.
Document emailed within 1 workday
Related Documents
Usman, M.; Syed, N.N.; Kakepoto, G.N.; Adil, S.N.; Khurshid, M. 2007: Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response Journal of the Association of Physicians of India 55: 103-107Cervantes, F.; Hernández-Boluda, J-Carlos.; Steegmann, J-Luis.; Conde, E.; Alvarez-Larrán, A.; López-Jiménez, J.; Osorio, S.; Villalón, Lía.; Camós, M.; García-Conde, J.; Odriozola, Jús. 2003: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88(10): 1117-1122
Sacha, T.; Czekalska, S.; Foryciarz, K.; Zawada, M.; Florek, I.; Cwynar, D.; Wator, G.; Balwierz, W.; Skotnicki, A.B. 2011: H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience Przeglad Lekarski 68(4): 191-195
Actis, G.C.; Maran, E.; Bonino, F.; Saracco, G.; Rosina, F.; Brunetto, M.R.; Baldi, M.; Rizzetto, M.; Verme, G.; Rocca, B. 1987: Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response Journal of Biological Regulators and Homeostatic Agents 1(1): 45-50
Ashariati, A.; Ugroseno, S. 2013: Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib Acta Medica Indonesiana 45(2): 107-113
Usman, M.; Kakepoto, G.N.; Adil, S.N.; Sajid, R.; Arain, S.; Khurshid, M. 2004: Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital Jpma. Journal of the Pakistan Medical Association 54(1): 17-20
Malagola, M.; Martinelli, G.; Rondoni, M.; Ottaviani, E.; Piccaluga, P.Paolo.; Ricci, P.; Visani, G.; Baccarani, M. 2004: Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission Haematologica 89(8): Ecr25
Smetana, K.; Pilcova, H.; Pluskalova, M.; Hrkal, Z. 2007: A karyometric study on ageing and butyrate or imatinib treated human leukemic myeloblasts represented by K562 cells originated from chronic myeloid leukaemia Neoplasma 54(5): 359-364
Goel, A.; Suri, J.C.; Aggarwal, K. 1992: Role of corticosteroids in the management of chronic obstructive lung disease: factors predicting response Indian Journal of Chest Diseases and Allied Sciences 34(1): 11-17
Stineman, M.G.; Williams, S.V. 1990: Predicting inpatient rehabilitation length of stay Archives of Physical Medicine and Rehabilitation 71(11): 881-887
Markuszewski, J.; Wierusz-Kozłowska, M.łg.; Woźniak, W.; Leśniewska, K.; Sobieska, M. 2009: Early acute phase response following total hip replacement Ortopedia, Traumatologia, Rehabilitacja 11(4): 324-332
Korenaga, M.; Hino, K.; Okita, K. 2001: A possible role of human leukocyte antigen(HLA) typing for predicting response to interferon therapy in chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 59(7): 1345-1350
Skarlos, D.V.; Bai, M.; Goussia, A.; Samantas, E.; Galani, E.; Tsavdaridis, D.; Karina, M.; Papakostas, P.; Konstantara, A.; Fountzilas, G. 2007: Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group Anticancer Research 27(4c): 2973-2983
Habib, F.K.; Chisholm, G.D. 1984: Hormonal receptors and other procedures for predicting clinical response in cancer of the prostate Archivos Espanoles de Urologia 37(Suppl 2): 751-759
Toner, G.C.; Geller, N.L.; Tan, C.; Nisselbaum, J.; Bosl, G.J. 1990: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors Cancer Research 50(18): 5904-5910
Juste, R.A.; Kwang, J.; de la Concha-Bermejillo, A. 1998: Dynamics of cell-associated viremia and antibody response during the early phase of lentivirus infection in sheep American Journal of Veterinary Research 59(5): 563-568
Balagula, Y.; Pulitzer, M.P.; Maki, R.G.; Myskowski, P.L. 2011: Pigmentary changes in a patient treated with imatinib Journal of Drugs in Dermatology: Jdd 10(9): 1062-1066
Su, J.B.; Hittinger, L.; Le Franc, P.; Crozatier, B. 1992: Limited left ventricular inotropic response to exercise in early phase of pressure overload in dogs American Journal of Physiology 263(4 Pt 2): H1011-H1016
Trznadel, K.; Luciak, M.; Paradowski, M.; Kubasiewicz-Ujma, B. 1989: Hemodialysis and the acute-phase response in chronic uremic patients International Journal of Artificial Organs 12(12): 762-765
Shiokawa, Y. 1987: Clinical study of the acute phase reaction. Acute phase proteins and a chronic inflammation, rheumatoid arthritis Nihon Rinsho. Japanese Journal of Clinical Medicine 45(5): 1068-1075